EE650 Cost Effectiveness of Siponimod for Secondary Progressive Multiple Sclerosis in Turkey

The objective of this study is to evaluate the cost effectiveness of siponimod vs natalizumab for SPMS from the Turkish public payer ’s (SGK) perspective.

Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: M Tatar, T Özbalas, B Saraçoğlu, Ç Ölmez, B Yarci, AC Akdemir, C Yılmaz, S Şen Source Type: research